Basal Cell and Squamous Cell Skin Cancers Guidelines

Vanderbilt-Ingram Cancer Center
Search for other papers by Vanderbilt-Ingram Cancer Center in
Current site
Google Scholar
Full access

Basal cell and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSCS), are the most common skin cancers. More than 1 million cases of NMSC are estimated to be diagnosed each year in the United States and their incidence is rising rapidly. Although rarely metastatic, basal cell and squamous cell cancers can produce substantial local destruction and disfigurement and may involve extensive areas of soft tissue, cartilage, and bone. Updates in the 2007 guidelines include changes to the principles of treatment for both basal cell and squamous cell skin cancers and changes in the consideration of radiotherapy.

For the most recent version of the guidelines, please visit

Vanderbilt-Ingram Cancer Center (VICC; is one of a select few NCI-designated centers in the Southeast and the only NCI-designated Comprehensive Cancer Center in Tennessee. Established under the leadership of Dr. Harold Moses in 1993, VICC brings together the cancer-related research, clinical care, education, prevention, and outreach activities at Vanderbilt University and Medical Center.

VICC's 250 faculty members in 7 research programs generate more than $135 million in research support from public and private sources. VICC focuses its efforts on high-impact basic and translational research and high quality multidisciplinary care, with particularly strong programs in phase I clinical trials, and lung, gastrointestinal, breast, head and neck, melanoma, pediatric, and hematologic malignancies. Its collaborative research initiatives include 3 Specialized Programs of Research Excellence, the Southern Community Cohort Study, and a U54 minority partnership with Meharry Medical College.

The center is led by interim director Jennifer A. Pietenpol, PhD (second photo on cover), Ingram Professor of Cancer Research, a biochemist with a research focus on tumor suppressor and cell cycle checkpoint signaling pathways. For more information about clinical trials, services, or second opinion consultation at VICC, call (800) 811-8480.

  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 786 107 10
PDF Downloads 415 61 5
EPUB Downloads 0 0 0